logo

In The Spotlight

Share

pharma-022218_14jan19.jpg Shares of Innoviva Inc. (INVA), which recently touched a new 52-week high of $19.82, are up 12% so far this month, slightly lagging behind the iShares NASDAQ Biotechnology Index (ETF) (IBB), which has gained 14% during the same period.

axonics-jan07.jpg Axonics Modulation Technologies Inc. (AXNX), which recently made its debut on the NASDAQ, is down nearly 2% so far this month while the iShares Nasdaq Biotechnology ETF index (IBB) has gained nearly 8% for the same period.

fleurstat-dec20.jpg Starpharma (SPHRY.OB), on Thursday, announced that it has licensed the sales and marketing rights of VivaGel BV in the United States to ITF Pharma, a subsidiary of Italfarmaco S.p.A, a privately held European specialty pharmaceutical company.

bank-dec18.jpg 2018 has been a banner year for healthcare IPOs in the U.S. - with more than 80 companies making a debut on the bourses compared to 50 in 2017. Let's take a look at some of the healthcare IPOs of 2018 that have delivered more than 50% returns.

achn-dec11.jpg Achillion Pharmaceuticals Inc. (ACHN), which is slated to report clinical data next week, has gained 7% so far this month.

osmotica-dec3.jpg Osmotica Pharmaceuticals plc (OSMT), which recently made its debut on the Nasdaq, is down 12% since its IPO while the iShares Nasdaq Biotechnology ETF (IBB) index has lost nearly 5% of its value for the same period.

catalyst-nov28.jpg Shares of Catalyst Pharmaceuticals Inc. (CPRX) have lost 26% of their value so far this year while the iShares Nasdaq Biotechnology ETF (IBB) has fallen about 2.6% during the same period.

nicord-nov22.jpg Shares of Gamida Cell Ltd. (GMDA) are up nearly 15% this month while the iShares Nasdaq Biotechnology ETF index (IBB) is down 1.55% for the same period.

cannabisleaf-nov19.jpg Of late, cannabis-related news and stocks have been garnering a lot of investor attention. Let's take a look at some of them.

liquida-nov15.jpg Shares of Liquidia Technologies Inc. (LQDA), which recently debuted on Nasdaq, are down more than 40% from their latest high.

maciepicel-nov07.jpg Shares of Vericel Corporation (VCEL) have gained an impressive 200% year-to-date, way ahead of the mere 0.9% returned by iShares Nasdaq Biotechnology ETF (IBB) for the same period.

immypharma-oct25.jpg Shares of Imprimis Pharmaceuticals Inc. (IMMY) have returned more than 110% year-to-date while the iShares Nasdaq Biotechnology ETF (IBB) has fallen 4% during the same period.

Follow RTT